IN8bio (NASDAQ:INAB – Get Free Report) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect IN8bio to announce earnings of ($0.3367) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.
IN8bio (NASDAQ:INAB – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.09. On average, analysts expect IN8bio to post ($1.49) EPS for the current fiscal year and ($1.24) EPS for the next fiscal year.
IN8bio Stock Up 1.0%
Shares of INAB opened at $0.91 on Tuesday. IN8bio has a 12-month low of $0.87 and a 12-month high of $2.73. The firm has a market capitalization of $8.97 million, a PE ratio of -0.56 and a beta of 0.30. The stock’s fifty day simple moving average is $1.15 and its 200-day simple moving average is $1.45.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of IN8bio in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.
Check Out Our Latest Research Report on IN8bio
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing ?? T cell therapeutic and ?? T cell engager (TCE) product candidates to address unmet medical needs. ?? T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic ?? T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.
Featured Stories
- Five stocks we like better than IN8bio
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
